2021
DOI: 10.1186/s13045-021-01047-9 View full text |Buy / Rent full text
|
|

Abstract: Background Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and safety of hetrombopag in ITP patients. Methods Patients who had not responded to or had relapsed after previous treatment were treated with an initial dosage of once-daily 2.5 or 5 mg hetrombopag (… Show more

Help me understand this report

Search citation statements

Order By: Relevance
0
0
0
0
0
3
10
0

Publication Types

Select...

Relationship

0
0

Authors

Journals